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OF SURVIVIN AND APOPTOSIS IN NASOPHARYNGEAL CARCINOMA 
TW01 CELLS
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Lumpur, Malaysia
The aim of this study is to investigate whether IL-6, IL-10 and TGF-β are able to confer resistance to apoptosis in nasopharyngeal car-
cinoma cells by upregulating the expression of survivin. Methods: The human nasopharyngeal carcinoma cell line TW01 (WHO NPC 
Type I) was cultured in DMEM-F12 Ham medium containing 10% FBS in a humidified atmosphere of 5% CO2 and 37◦C and treated 
with different concentrations of IL-6, IL-10 and TGF-β. Survivin mRNA expression was measured by real-time quantitative PCR and 
Western blot. Apoptosis was determined based on the assay for caspase-3 activity. Results: Of all the cytokines tested, only TGF-β 
(10 pg/mL) induced the over-expression of survivin at a significant level and this correlated with resistance to apoptosis (p ≤ 0.05). 
To confirm if survivin is responsible for resistance to apoptosis, YM155 which is a survivin inhibitor was used and the results showed that 
YM155 abrogated the protective effect of TGF-β. Interestingly, IL-10 did not significantly alter the expression of survivin. Conclusions: 
We conclude that TGF-β up-regulates the expression of survivin leading to the resistance to apoptosis in NPC TW01 cells.
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Nasopharyngeal carcinoma (NPC) is a tumor aris-
ing from the epithelial cells that line and covers the 
surface of the nasopharynx. It develops most often 
within the lateral nasopharyngeal recess or fossa 
of Rosenmuller [1]. NPC occurs more frequently 
in males as compared to females with incidence rates 
commonly two to three times higher in males as com-
pared to his female counterparts. According to world 
area, incidence rates are highest in South-Eastern Asia, 
namely Hong Kong and Guangdong, and in other parts 
of Southern Asia namely, the Philippines and Thailand 
[2, 3]. Globally, the three highest national incidence 
rates are estimated in Malaysia, Indonesia, and Singa-
pore, where rates are high among the Cantonese Chi-
nese and Malay populations [4]. The prevalence of this 
malignancy are considerably lower in most populations 
Americas, Europe, Africa, Central and Eastern Asia.
The World Health Organization (WHO) divides NPC 
into three histological types based on their degree of dif-
ferentiation with the WHO Type II being more prevalent 
in Asia and is strongly associated with Epstein — Barr 
virus (EBV) [5]. NPC has viral, genetic and environ-
mental components to its etiology [6].
Analysis of NPC biopsies revealed the expression 
of a panel of cytokines: interleukin (IL)-1a, IL-1b, IL-2, 
IL-4, IL-5, IL-6, IL-10, IFN-γ, TNF- and TGF-β[7]. These 
cytokines are functionally important in shaping the NPC 
microenvironment. Differential blood levels of IL-6, IL-
10 and TGF-β have been reported in patients with NPC 
as compared to healthy controls [8]. Thus, it is fascinating 
to know if these cytokines are involved in the promotion 
of malignant phenotype through one of the cardinal fea-
tures of cancer that is, resistance to apoptosis.
Protection from apoptosis can be achieved through 
up-regulation of anti-apoptotic mediators such as sur-
vivin [9]. The expression of survivin in NPC cells was 
reported to be triggered by the Epstein — Barr virus 
latent membrane protein 1 (EBV LMP1) [10].
Survivin, also known as Baculoviral IAP Repeat-
Containing Protein 5 (BIRC5), is a member of the 
inhibi tors of apoptosis (IAP)/BIRP gene family [11]. 
Survivin or BIRC5 is known to prevent cells from 
undergoing apoptosis by inhibiting caspases and 
promotes cell growth through stabilizing microtubules 
during cell mitosis [12]. In cancer cells, elevated Sur-
vivin is commonly associated with enhanced prolif-
erative index [13, 14], reduced levels of apoptosis 
[15, 16], resistance to chemotherapy [17, 18], and 
increased rate of tumor recurrence [19].
The purpose of the present study was to inves-
tigate the effects of IL-6, IL-10 and TGF-β on the 
expression levels of survivin and subsequently its 
protective effect against apoptosis in the nasopha-
ryngeal TW01 cells.
MATERIALS AND METHODS
Antibodies and reagents. In the study, antibodies 
(Ab) to survivin (Cell Signalling Technology, INC, USA), 
anti-rabbit IgG, HRP-linked Ab (Cell Signalling Tech-
nology, INC, USA) and survivin inhibitor, YM155 (Sell-
eck Chemicals, USA) were used.
Cell culture. The human NPC cell line TW01 (WHO 
NPC Type I) was maintained in monolayer cultures 
in Dulbecco’s Modified Eagle’s medium (Gibco, 
California, USA) containing 10% fetal bovine serum 
(Gibco, California, USA) in a humidified atmosphere 
of 5% CO2 and 37oC.
Cytokine treatment. Cytokines: IL-6, IL-10 and 
TGF-β with concentrations of 10 pg/mL, 100 pg/mL and 
1000 pg/mL respectively were used. Duration of treat-
ment was 3 h prior to any tests carried out on the cells.
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RNA extraction and RNA quantification by spec-
tral absorbance. Total RNA was extracted using the 
RNeasy Mini Kit (QIAGEN, Germany) as per manufac-
turer’s instructions. Total RNA was quantified using ab-
sorption of light at 260 and 280 nm (A260/A280) using 
the Infinite® 200 PRO NanoQuant (Tecan, Switzerland). 
Reverse-transcriptase polymerase chain reac-
tion (RT-PCR). Survivin mRNA expression was mea-
sured by RT-PCR. The first-strand cDNA was generated 
in a 20 μL RT reaction containing 1 μg of total RNA 
as template, random primers from the TaqMan® Gene 
Expression Assays (Applied Biosystems, California, USA), 
and TaqMan® RNA-to-CT™ 1-Step Kit reverse transcrip-
tase (Applied Biosystems, Foster City, CA). The cDNA 
product was subjected to 40 cycles of amplification with 
appropriate primers using the iQ5 iCycler™ Real-time PCR 
system (Bio-Rad, USA). Cycling conditions were denatu-
ration at 95oC for 15 s, annealing at 60oC for 1 min and ex-
tension at 60oC for 1 min. Amplification reaction for each 
sample and standard was performed in triplicates. The 
survivin primer used was BIRC5 (assay ID Hs_00153353_
m1) purchased from Applied Biosystems, California, 
USA. GAPDH expression was used as house-keeping 
gene; therefore, amplification signals for survivin mRNA 
were normalized to the respective amplification signals 
of GAPDH mRNA. The delta-delta CT (2-CT) method was 
used for the quantification of mRNA levels.
Western blotting. Western blot was used to de-
termine the expression of survivin in cells treated with 
TGF-β of 10 pg/mL concentration, cells treated with 
TGF-β of 10 pg/mL concentration together with survivin 
inhibitor, YM155 and non-treated cells. The protein con-
centration of cells was determined using the Bradford 
assay method. Survivin was detected using rabbit anti-
survivin IgG followed by detection with chemiluminescent 
agent. 
Apoptosis assay. Caspase-3 activity in cell lysates 
was measured using the Caspase-3 Colourimetric Assay 
kit™ (Sigma, USA) according to the manufacturer’s pro-
tocols. Briefly, the caspase-3 colorimetric assay is based 
on the hydrolysis of the peptide substrate acetyl-Asp-
Glu-ValAsp p-nitroanilide (Ac-DEVD-pNA) by caspase-3, 
resulting in the release of the p-nitroaniline (pNA) moiety. 
p-Nitroaniline has a high absorbance at 405 nm (εmM = 
10.5). The concentration of the pNA released from the sub-
strate is calculated from the absorbance values at 405 nm. 
Statistical methods. The Wilcoxon rank-sum 
test was used to assess apoptotic index (AI) between 
TW01 treated cells and TW01 non-treated cells. 
Statistical analysis was performed using the SPSS 
17.0 software. Generally, a p-value ≤ 0.05 was con-
sidered to imply statistical significance. 
RESULTS
Apoptotic index in NPC cells pre-treated with 
cytokines. The response of TW01 cells treated with 
different cytokines of different concentrations to apop-
totic stimulus was assessed base on the enzymatic 
activity of caspase-3 [21]. Apoptosis was stimulated 
with staurosporine (1 μg/mL) from Streptomyces sp. 
(Sigma Aldrich, USA). Fig. 1 illustrates the apoptotic 
index of TW01 treated with different cytokines. The 
control consisted of cells that were not treated with 
cytokines. The apoptotic index was calculated from the 
ratio of induced cells divided by the non-induced cells. 
An average value from readings of triplicates was used. 
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Fig. 1. Apoptotic index of TW01 cells treated with cytokines 
at concentrations: 10 pg/mL, 100 pg/mL and 1000 pg/mL re-
spectively. The level of apoptosis correlates with the level of hy-
drolyzed pNA measured at 405 nm. Each boxplot represents the 
average value for assays conducted in triplicates. The symbol 
‘*’ indicates significant p-value ≤ 0.05
TW01 cells that were treated with IL-6 (100 pg/
mL), IL-10 (1000 pg/mL), TGF-β (10 pg/mL) and TGF-β 
(100 pg/mL) resulted in significantly lower apoptotic in-
dices (p ≤ 0.05), while IL-6 (10 pg/mL and 1000 pg/mL) 
generated significantly higher apoptotic indices. This 
comparison was made with the “control” which were 
cells not treated with any cytokine. There are cells which 
showed no significant findings: cells treated with IL-
10 at 10 pg/mL (p = 0.127) and 100 pg/mL (p = 0.513) 
concentration and also TGF-b at 1000 pg/mL (p = 0.827).
Over-expression of survivin in TGF-β (10 pg/mL) 
treated cells. Over-expression of survivin in response 
to TGF-β (10 pg/mL) treatment was demonstrated 
in the results obtained from real-time quantitive-
PCR. This correlated with the results from the apop-
tosis assay in which cells treated TGF-β had a lower 
apoptotic index as compared to the others. 
Fig. 2 illustrates the gene expression of survivin in all 
TW01 cells treated with different cytokines of different 
concentrations. The 2-CT method was used to quantify 
the mRNA levels. GAPDH expression was used as the 
house-keeping gene, whereby amplification signals for 
survivin mRNA were normalized to the respective ampli-
fication signals of GAPDH mRNA. Interestingly, survivin 
mRNA expression was increased in TW01 cells treated 
with TGF-β (10 pg/mL). The normalized fold expression 
of TGF-β (10 pg/mL) was 11.31 (SD ± 2.98). The dif-
ferential expression of survivin in all the other treated 
cells was not sigbnificant. An inverse correlation be-
tween survivin expression and apoptotic index was 
noted in a study conducted by Rodel et al. [22], high 
survivin expression was associated with low median 
apoptotic index. Conversely, low survivin expression 
was associated with a high median apoptotic index .
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Fig. 2. Normalized fold expression of survivin mRNA levels 
in TW01 treated cells. Total mRNA of TW01 cells were extracted. 
Level of survivin mRNA was determined by real-time PCR (RT-
PCR). The delta-delta CT (2-CT) method was used for the quan-
tification of mRNA levels. Survivin mRNA levels in cells treated 
with TGF-β (10 pg/mL) was elevated to 11.31 with a standard 
deviation value of 2.98
Survivin inhibitor reverses resistance to apopto-
sis effect. Protection from apoptosis can be achieved 
through the up-regulation of anti-apoptotic mediators 
such as proteins from the INK4 family [23] and survivin 
[9]. In order to ascertain that survivin is the anti-apoptotic 
mediator responsible for the protection of cells against 
apoptosis, a survivin inhibitor, YM155 was incubated 
together with TGF-β (10 pg/mL) together with staurospo-
rine for three hours prior to the apoptosis assay. The final 
concentration of YM155 used was 500 nmol/L. As ob-
served, cells treated only with TGF-β (10 pg/mL) had 
a low apoptotic index (AI) while in those treated with 
YM155 the apoptotic index was seen to increase as sur-
vivin was inhibited in comparison to the control which 
was neither treated with TGF-β (10 pg/mL) nor YM155.
Expression of survivin analyzed via Western 
blotting. Western blotting was performed in order 
to investigate the corresponding expression of survivin 
at the protein level. In agreement with results from RT-
PCR (Fig. 2), the protein levels of survivin were higher 
in cells treated with TGF-β (10 pg/mL) and significantly 
reduced in the presence of YM155 (Fig. 3). 
Survivin
Actin
Control TGF-β (10 pg/mL)
+ YM 155
TGF-β (10 pg/mL)
Fig. 3. Western blotting analysis of the expression of Survivin 
at the protein level. TW01 cells were subjected to 3 forms of treat-
ment i.e. those treated with TGF-β (10 pg/mL), those treated with 
TGF-β (10 pg/mL) + YM155 and those not treated, named control 
in the diagram. Western blotting was then performed to analyze 
the expression of survivin at the protein level. Actin expression 
served as the control
DISCUSSION
The ability of cancer cells to by-pass apoptosis 
and continue to proliferate is one of the fundamental 
hallmarks of cancer development and progression 
[24]. Effector caspases are caspases that execute 
apoptosis [25, 26]. In normal conditions, caspase 
activity is held in check by the IAP protein family, 
namely survivin, XIAP, cIAP2 etc and c-FLIP [27]. Al-
though these proteins are not directly involved in the 
apoptotic signaling pathway, cell death can be averted 
via the suppression of initiator and effector caspase 
activity. It has been reported that the IAPs: survivin and 
cIAP1 are over expressed in several malignancies [28].
This leads us to the objective of this study which 
is to investigate the effects of IL-6, IL-10, and 
TGF-β on the expression of survivin and its protective ef-
fect against apoptosis. Several studies have been done 
on cytokines: IL-1, IL-2, IL-3, IL-5 and IL-8 and their 
relations to NPC [7, 29, 30]. There are also some stu-
dies done on our cytokines of interest, however, to date, 
no investigation had been carried out investigate the 
effects of IL-6, IL-10, and TGF-β of 3 different concen-
trations respectively on the expression of survivin. 
The concentration of IL-6, IL-10, and TGF-β chosen 
for this study was based on a previous study conducted 
by Tan et al. [8]. In that study, levels of IL-6, IL-10, and 
TGF-β were found to differ amongst NPC patients 
pre- and post-treatment. Results from that investiga-
tion showed that high levels of IL-6 (164 ± 37 pg/mL) 
were seen in untreated NPC patients indicating that 
high IL-6 levels played a role in tumor progression. 
As for IL-10, there were no variations in the cyto-
kine levels of plasma in pre- and post-treated NPC 
patients. In untreated patients, lower levels of TGF-β 
(6368 ± 682 pg/mL) were recorded, indicating that 
lower levels of TGF-β played a role in tumor progres-
sion. Therefore, it was decided for each cytokine, the 
concentrations used would be 10 pg/mL, 100 pg/mL and 
1000 pg/mL.
In our study, it was found that apoptotic indices of cells 
treated with different cytokines were concentration-de-
pendent. IL-6 is a growth factor that regulates cell prolif-
eration, metabolism and survival [31] and is known to play 
pivotal roles in cell differentiation and tumor progression 
[32]. Nevertheless, its involvement in cancer is quite 
dubious, as IL-6 can play both tumor-suppressive roles 
as well as tumor-progressive roles, depending on the 
type of cancer involved [33, 34]. As observed in Fig. 1, 
IL-6 at concentrations of 10 pg/mL and 1000 pg/mL re-
sulted in apoptotic indices that were significantly higher 
as compared to the non-treated cells (p ≤ 0.05). On the 
other hand, the apoptotic index of cells treated with 
IL-6 (100 pg/mL) was significantly lower (p ≤ 0.05). 
This showed that in concentrations of 10 pg/mL and 
1000 pg/mL, IL-6 did not confer protection against 
apoptosis as high apoptotic indices were observed, 
nonetheless, IL-6 in concentrations of 100 pg/mL con-
ferred protection against apoptosis.
This phenomenon can also be observed in IL-10 trea-
ted cells, where at certain concentrations, the apoptotic 
index was low while at other concentrations, the apop-
totic index was high. At concentrations of 10 pg/mL and 
100 pg/mL, apoptotic indices were non-significant (p > 
0.05) while at the concentration of 1000 pg/mL, a sig-
nificantly lower (p ≤ 0.05) than the control apoptotic 
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index was observed.This can be explained in an animal 
study by Stuhler et al. [35] showing that IL-10 can either 
promote or inhibit the progression of tumors.
The question to whether TGF-β plays a tumor-
suppressive or tumor-promoting role is still unknown. 
However, based on this study, the apoptotic index 
in TW01 cells was correlated positive to increasing con-
centrations of TGF-β (Fig. 1). It can be concluded that 
TGF-β (10 pg/mL) and TGF-β (100 pg/mL) protected 
the cells from apoptosis with a significantly lower 
apoptotic index as compared to the control (p ≤ 0.05) 
but not at TGF-β 1000 pg/mL. 
Numerous reports have examined the role of sur-
vivin in cancer. Survivin, a dimericbaculovirus inhibitor 
of apoptosis is a newly discovered IAP which plays 
an important role in both inhibition of apoptosis and 
cell division regulation [36]. Survivin plays an important 
role in the suppression of apoptosis by either directly 
or indirectly inhibiting the activity of caspases [27]. Cas-
pases are cell death proteases that induce apoptosis. 
There are studies indicating that survivin directly binds 
to caspase-3, inhibiting its activity in vitro [37–39]. 
In the present study, we found that TGF-β of 10 pg/
mL concentration up regulated the expression of sur-
vivin. The results from RT-PCR showed an astounding 
11.31 normalized fold increase in the expression level 
(Fig. 2). As for the other cells treated with IL-6 and IL-
10 at different concentrations, no significant increase 
in survivin expression was observed. The findings 
in our study were in line with that of Rodel et al. as the 
apoptotic index in cells treated with TGF-β of 10 pg/
mL concentration was amongst the lowest.
To determine if survivin was solely responsible for 
the resistance to apoptosis in cells treated with TGF-β
(10 pg/mL), a co-treatment with survivin inhibitor, 
YM155 was performed. YM155 is an inhibitor of the sur-
vivin expression [40]. As evident in Fig. 2, the protein 
levels of survivin were high in cells treated with TGF-β 
(10 pg/mL) and significantly reduced in the presence 
of YM155 and this correlated to the abrogation of re-
sistance to apoptosis (Fig. 4).
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Fig. 4. Apoptotic index of TW01 cells treated with TGF-β 
(10 pg/mL), YM155 and non-treated cells. Bar chart reveals 
that cells treated only with TGF-β (10 pg/mL) had a low apop-
totic index (AI) while in those treated with YM155; the apoptotic 
index was seen to increase as survivin is inhibited in comparison 
to the control which was neither treated with TGF-β (10 pg/mL) 
nor YM155. Each bar represents the average value for assays 
conducted in triplicates
We conclude that TGF-β conferred protection 
to apoptosis in NPC TW01 cells by up-regulating the 
expression of survivin. IL-6 and IL-10 did not signifi-
cantly alter the expression of survivin, and thus did not 
confer protection against apoptosis.
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